Skip to main content
Log in

Intrathecal neurolytic block in a patient with refractory cancer pain

  • Clinical Report
  • Published:
Journal of Anesthesia Aims and scope Submit manuscript

Abstract

We report the successful treatment of refractory cancer pain by bilateral intrathecal neurolysis using phenol–glycerol. A 60-year-old man had recurrent sigmoid cancer and metastases to the lumbar (L4–5) and sacral bones. He complained of refractory pain in the lower back and lower extremities despite high-dose opioid treatment based on the WHO ladder. On admission to our hospital, he received continuous intravenous infusion of morphine (7,000 mg/day) with ketamine (300 mg/day) and lidocaine (700 mg/day). Intravenous midazolam was required to treat extreme anxiety. Because of inadequate pain relief and severe drowsiness, intrathecal phenol–glycerol neurolytic block was performed twice at the L2/3 intervertebral space. His analgesia was greatly improved and high-dose intravenous opioid was retitrated and ceased. He remained comfortable and lucid at home for 2 months, until 2 days before his death at hospital. Intrathecal neurolytic block may be appropriate for some patients suffering from refractory pain that is resistant to conventional opioid analgesic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. World Health Organization. Cancer Pain Relief. Albany: WHO Publications Center; 1986.

  2. Zech DF, Grond S, Lynch J, Hertel D, Lehmann KA. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain. 1995;63:65–76.

    Article  PubMed  CAS  Google Scholar 

  3. Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health Organization analgesic ladder? Cancer Control. 2000;7:149–56.

    PubMed  CAS  Google Scholar 

  4. Sloan PA. The evolving role of interventional pain management in oncology. J Support Oncol. 2004;2:491–500.

    PubMed  Google Scholar 

  5. Jackson TP, Gaeta R. Neurolytic blocks revisited. Curr Pain Headache Rep. 2008;12:7–13.

    Article  PubMed  Google Scholar 

  6. Tei Y, Morita T, Nakaho T, Takigawa C, Higuchi A, Suga A, Tajima T, Ikenaga M, Higuchi H, Shimoyama N, Fujimoto M. Treatment efficacy of neural blockade in specialized palliative care services in Japan: a multicenter audit survey. J Pain Symptom Manage. 2008;36:461–7.

    Article  PubMed  Google Scholar 

  7. Chambers WA. Nerve blocks in palliative care. Br J Anaesth. 2008;101:95–100.

    Article  PubMed  CAS  Google Scholar 

  8. Tay W, Ho KY. The role of interventional therapies in cancer pain management. Ann Acad Med Singapore. 2009;38:989–97.

    PubMed  Google Scholar 

  9. Christo PJ, Mazloomdoost D. Interventional pain treatments for cancer pain. Ann NY Acad Sci. 2008;1138:299–328.

    Article  PubMed  Google Scholar 

  10. Gerbershagen HU. Neurolysis. Subarachnoid neurolytic blockade. Acta Anaesthesiol Belg. 1981;32:45–57.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Akihiko Watanabe.

About this article

Cite this article

Watanabe, A., Yamakage, M. Intrathecal neurolytic block in a patient with refractory cancer pain. J Anesth 25, 603–605 (2011). https://doi.org/10.1007/s00540-011-1141-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00540-011-1141-4

Keywords

Navigation